AbbVie Inc. (ABBV)
$
223.01
+2.58 (1.16%)
Key metrics
Financial statements
Free cash flow per share
11.6078
Market cap
394.1 Billion
Price to sales ratio
6.6083
Debt to equity
-26.0193
Current ratio
0.7245
Income quality
3.1116
Average inventory
4.9 Billion
ROE
4.9750
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide, offering a diverse portfolio of therapies. The company reported a substantial revenue of $56,334,000,000.00 reflecting its strong market presence. Among its key offerings are HUMIRA, an injection therapy for autoimmune and intestinal Behçet's diseases, and SKYRIZI, which treats moderate to severe plaque psoriasis in adults. Additionally, RINVOQ serves as a JAK inhibitor for moderate to severe active rheumatoid arthritis, while IMBRUVICA and VENCLEXTA are utilized for chronic lymphocytic leukemia and small lymphocytic lymphoma treatment. MAVYRET targets chronic HCV genotype 1-6 infections, and the company also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency. Furthermore, Synthroid is used for hypothyroidism, while Linzess/Constella addresses irritable bowel syndrome with constipation. Lupron targets advanced prostate cancer and other conditions, and Botox therapeutic is part of their offerings. AbbVie continues its innovation with ORILISSA, a treatment for endometriosis pain, and Duopa and Duodopa, which help manage Parkinson's disease. The company’s ophthalmic products include Lumigan/Ganfort for elevated intraocular pressure and Restasis, which boosts tear production. The gross profit ratio is 0.70 reflecting the efficiency of the company's production and sales operations. The earnings per share (EPS) is reported at $2.40 indicating the company's profitability on a per-share basis. Moreover, the net total of other income and expenses is -$5,421,000,000.00 reflecting non-core financial activities, while the weighted average number of shares outstanding is 1,769,000,000.00 highlighting the company's shareholder base. In the financial market, the stock is reasonably priced at $222.47 appealing to a broad range of investors. AbbVie has a high average trading volume of 6,193,301.00 indicating strong liquidity, and boasts a large market capitalization of $394,143,413,800.00 establishing it as a dominant player. It is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape, and belongs to the Healthcare sector, driving innovation and growth. This robust combination of research, product diversity, and solid financial metrics underpins AbbVie's position as a leader in the pharmaceutical market.
Is AbbVie Inc. (ABBV) a good investment?
Investing in AbbVie Inc. (ABBV) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is AbbVie Inc. (ABBV)'s stock forecast?
Analysts predict AbbVie Inc. stock to fluctuate between $164.39 (low) and $244.81 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is AbbVie Inc.'s market capitalization?
As of 2026-01-30, AbbVie Inc.'s market cap is $394,143,413,800, based on 1,767,380,000 outstanding shares.
How does AbbVie Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., AbbVie Inc. has a Lower Market-Cap, indicating a difference in performance.
Does AbbVie Inc. pay dividends?
AbbVie Inc. pays dividends. The current dividend yield is 3.10%, with a payout of $1.73 per share.
How can I buy AbbVie Inc. (ABBV) stock?
To buy AbbVie Inc. (ABBV) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABBV. Place an order (Market, Limit, etc.).
What is the best time to invest in AbbVie Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did AbbVie Inc. perform in the last earnings report?
Revenue: $56,334,000,000 | EPS: $2.40 | Growth: -12.09%.
Where can I find AbbVie Inc.'s investor relations reports?
Visit https://www.abbvie.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for AbbVie Inc.?
You can explore historical data from here
What is the all-time high and low for AbbVie Inc. stock?
All-time high: $244.81 (2025-10-01) | All-time low: $105.56 (2021-09-20).
What are the key trends affecting AbbVie Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Investors need to pay close attention to ABBV stock based on the movements in the options market lately.
businesswire.com
CHICAGO--(BUSINESS WIRE)--The AbbVie Foundation, a 501(c)(3) nonprofit working to drive transformative change and advance health equity in communities worldwide, in partnership with MATTER, the premier health care incubator and innovation hub, announced today a call for applications for the 2026 AbbVie Foundation Health Equity Accelerator. Now in its second year, the accelerator provides resources and coaching to select nonprofit organizations to advance their innovative solutions that expand a.
defenseworld.net
Belpointe Asset Management LLC increased its holdings in AbbVie Inc. (NYSE: ABBV) by 7.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 35,648 shares of the company's stock after acquiring an additional 2,618 shares during the quarter. Belpointe
fool.com
AbbVie is a Dividend King with a juicy yield. Coca-Cola has increased its dividend for 63 consecutive years and will likely soon extend that streak.
seekingalpha.com
Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%, though 14 Kings outperformed the index. 2026 began strongly for Dividend Kings, up 4.66% through January 23rd, outpacing SPY's 1.07% gain. Nineteen Dividend Kings appear both potentially undervalued and offer long-term annualized expected returns of at least 10%.
defenseworld.net
First Citizens Bank and Trust Co. trimmed its position in shares of AbbVie Inc. (NYSE: ABBV) by 6.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,834 shares of the company's stock after selling 2,433 shares
fool.com
Alphabet and Nvidia offer investors a smart way to get exposure to the AI wave. AbbVie and Interactive Brokers can prove to be resilient long-term picks.
fool.com
Eli Lilly has outstanding growth prospects thanks to its leadership in its core therapeutic area. AbbVie's immunosuppressant portfolio helps it to produce steady revenue and profits.
fool.com
AbbVie has increased its dividend by 333% since 2013. Coca-Cola is a Dividend King that still has plenty of growth potential.
See all news
